Pioglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, was also found to modulate the progression of renal fibrosis and ameliorate DN in diabetic model [34]. The gene discussed is PPARG; the disease is renal fibrosis.